Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Immunization delays the onset of prion disease in mice.

Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T.

Am J Pathol. 2002 Jul;161(1):13-7.

2.

Anti-prion antibodies for prophylaxis following prion exposure in mice.

Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T.

Neurosci Lett. 2003 Jan 23;336(3):185-7.

PMID:
12505623
3.

Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion.

Ishibashi D, Yamanaka H, Yamaguchi N, Yoshikawa D, Nakamura R, Okimura N, Yamaguchi Y, Shigematsu K, Katamine S, Sakaguchi S.

Vaccine. 2007 Jan 22;25(6):985-92. Epub 2006 Oct 6.

PMID:
17055125
4.

Immunotherapy in prion disease.

Roettger Y, Du Y, Bacher M, Zerr I, Dodel R, Bach JP.

Nat Rev Neurol. 2013 Feb;9(2):98-105. doi: 10.1038/nrneurol.2012.258. Epub 2012 Dec 18. Review.

PMID:
23247613
5.

Mucosal vaccination delays or prevents prion infection via an oral route.

Goñi F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, Carp R, Meeker HC, Rubenstein R, Brown DR, Sy MS, Chabalgoity JA, Sigurdsson EM, Wisniewski T.

Neuroscience. 2005;133(2):413-21.

PMID:
15878645
6.

Immunization with recombinant prion protein leads to partial protection in a murine model of TSEs through a novel mechanism.

Xanthopoulos K, Lagoudaki R, Kontana A, Kyratsous C, Panagiotidis C, Grigoriadis N, Yiangou M, Sklaviadis T.

PLoS One. 2013;8(3):e59143. doi: 10.1371/journal.pone.0059143. Epub 2013 Mar 15.

7.

Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection.

Polymenidou M, Heppner FL, Pellicioli EC, Urich E, Miele G, Braun N, Wopfner F, Schätzl HM, Becher B, Aguzzi A.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14670-6. Epub 2004 Aug 3.

8.

Vaccine approaches to prevent and treat prion infection : progress and challenges.

Müller-Schiffmann A, Korth C.

BioDrugs. 2008;22(1):45-52. Review.

PMID:
18215090
9.

Prospects for preventative vaccines against prion diseases.

Sakaguchi S.

Protein Pept Lett. 2009;16(3):260-70. Review.

PMID:
19275739
10.

Immunomodulation for prion and prion-related diseases.

Wisniewski T, Goñi F.

Expert Rev Vaccines. 2010 Dec;9(12):1441-52. doi: 10.1586/erv.10.131. Review.

11.

Antigenic mimicry-mediated anti-prion effects induced by bacterial enzyme succinylarginine dihydrolase in mice.

Ishibashi D, Yamanaka H, Mori T, Yamaguchi N, Yamaguchi Y, Nishida N, Sakaguchi S.

Vaccine. 2011 Nov 21;29(50):9321-8. doi: 10.1016/j.vaccine.2011.10.017. Epub 2011 Oct 18.

PMID:
22008817
12.

Therapeutics and prion disease: can immunisation or drugs be effective?

Sassoon J, Sadowski M, Wisniewski T, Brown DR.

Mini Rev Med Chem. 2005 Apr;5(4):361-6. Review.

PMID:
15853626
13.

Immunotherapy as a therapeutic treatment for neurodegenerative disorders.

White AR, Hawke SH.

J Neurochem. 2003 Nov;87(4):801-8. Review.

14.

Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene.

Korth C, Kaneko K, Groth D, Heye N, Telling G, Mastrianni J, Parchi P, Gambetti P, Will R, Ironside J, Heinrich C, Tremblay P, DeArmond SJ, Prusiner SB.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4784-9. Epub 2003 Apr 8.

15.

High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice.

Goñi F, Prelli F, Schreiber F, Scholtzova H, Chung E, Kascsak R, Brown DR, Sigurdsson EM, Chabalgoity JA, Wisniewski T.

Neuroscience. 2008 May 15;153(3):679-86. doi: 10.1016/j.neuroscience.2008.02.051. Epub 2008 Mar 6.

16.

Promising developments bringing prion diseases closer to therapy and prophylaxis.

Gilch S, Schätzl HM.

Trends Mol Med. 2003 Sep;9(9):367-9. Review.

PMID:
13129701
17.

Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses.

Kaiser-Schulz G, Heit A, Quintanilla-Martinez L, Hammerschmidt F, Hess S, Jennen L, Rezaei H, Wagner H, Schätzl HM.

J Immunol. 2007 Sep 1;179(5):2797-807.

18.

Therapeutic approaches for prion and Alzheimer's diseases.

Wisniewski T, Sigurdsson EM.

FEBS J. 2007 Aug;274(15):3784-98. Epub 2007 Jul 6. Review.

19.

Vaccines for conformational disorders.

Sadowski M, Wisniewski T.

Expert Rev Vaccines. 2004 Jun;3(3):279-90. Review.

PMID:
15176944
20.

Electrotransfer of cDNA coding for a heterologous prion protein generates autoantibodies against native murine prion protein in wild-type mice.

Alexandrenne C, Wijkhuisen A, Dkhissi F, Hanoux V, Priam F, Allard B, Boquet D, Couraud JY.

DNA Cell Biol. 2010 Mar;29(3):121-31. doi: 10.1089/dna.2009.0940.

PMID:
20025536

Supplemental Content

Support Center